Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents

Haematologica. 2017 Mar;102(3):e104-e107. doi: 10.3324/haematol.2016.154070. Epub 2016 Dec 1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / genetics*
  • Bortezomib / therapeutic use
  • Disease Progression
  • Gene Expression
  • Humans
  • Immunoglobulin Light Chains / blood
  • Immunoglobulin Light Chains / genetics*
  • Immunoglobulin M / blood
  • Immunoglobulin M / genetics*
  • Immunoglobulins / blood
  • Immunoglobulins / genetics*
  • Lenalidomide
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / genetics
  • Multiple Myeloma / mortality
  • Multiple Myeloma / therapy
  • Prognosis
  • Recurrence
  • Stem Cell Transplantation
  • Survival Analysis
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Immunoglobulin Light Chains
  • Immunoglobulin M
  • Immunoglobulins
  • M-proteins (Myeloma)
  • Thalidomide
  • Bortezomib
  • Lenalidomide